<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03411304</url>
  </required_header>
  <id_info>
    <org_study_id>2017/080/HP</org_study_id>
    <nct_id>NCT03411304</nct_id>
  </id_info>
  <brief_title>Aortic Stenosis: Determinants and Prognostic Value of Preoperative Left Ventricular Remodeling After Valvular Replacement</brief_title>
  <official_title>Aortic Stenosis: Determinants and Prognostic Value of Preoperative Left Ventricular Remodeling After Valvular Replacement (AS-INTERVENTION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence&#xD;
      of AS is constantly increasing due to the aging of the population. Although significant&#xD;
      progress has been made in understanding the pathophysiological mechanisms underlying the&#xD;
      onset and progression of AS, there is no medical treatment to slow or prevent its&#xD;
      progression. The only treatment available is Aortic Valve Replacement (AVR) performed by&#xD;
      surgery or by catheterization (TAVI).&#xD;
&#xD;
      AS is associated with an increase of post-load which leads the left ventricular myocardium to&#xD;
      hypertrophy. Associated with hypertrophy, myocardial fibrosis will gradually develop. Despite&#xD;
      interesting data, many unknowns persist and remain to be identified.&#xD;
&#xD;
      The aim of the study is to characterize prospectively the left ventricular remodeling and&#xD;
      assess its changes after AVR and within 1 year in 500 patients using clinical, biological,&#xD;
      echocardiographic and MRI parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of clinical events according to left ventricular remodeling</measure>
    <time_frame>Year 1</time_frame>
    <description>Echocardiography and MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinical events according to left ventricular remodeling</measure>
    <time_frame>Year 2</time_frame>
    <description>Echocardiography and MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinical events according to left ventricular remodeling</measure>
    <time_frame>Year 3</time_frame>
    <description>Echocardiography and MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinical events according to left ventricular remodeling</measure>
    <time_frame>Year 4</time_frame>
    <description>Echocardiography and MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of left ventricular remodeling after aortic valvular replacement</measure>
    <time_frame>Year 1</time_frame>
    <description>Echocardiography and MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of persistence and type of left ventricular remodeling</measure>
    <time_frame>Year 1</time_frame>
    <description>Echocardiography and MRI Occurence of clinical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of fibrosis</measure>
    <time_frame>Year 1</time_frame>
    <description>Echocardiography and MRI Occurence of clinical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biomarkers</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">440</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with at least moderate aortic stenosis and in whom an intervention is programmed&#xD;
        or indicated&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aortic stenosis&#xD;
&#xD;
          -  Indication of Aortic Valve Replacement (Surgery or TAVI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatismal or congenital aortic stenosis&#xD;
&#xD;
          -  Aortic insufficiency (grade &gt;= 2/4)&#xD;
&#xD;
          -  Associated valvulopathy (grade &gt;= 2/4)&#xD;
&#xD;
          -  Myocardial infarction antecedent&#xD;
&#xD;
          -  Severe renal failure&#xD;
&#xD;
          -  Cardiac surgery (Aorta abdominal) antecedent&#xD;
&#xD;
          -  Complex congenital cardiopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helene Eltchaninoff, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valvular replacement</keyword>
  <keyword>Aortic stenosis</keyword>
  <keyword>Left ventricular remodeling</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

